(4-氯-2-甲酰基苯氧基)乙酸 | 14440-47-2

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4-氯-2-甲酰基苯氧基)乙酸
• 英文名称: (4-chloro-2-formylphenoxy)acetic acid
• 英文别名: (4-Chlor-2-formyl-phenoxy)-essigsaeure；2-formyl-4-chlorophenoxyacetic acid；2-(4-chloro-2-formylphenoxy)acetic acid
• CAS: 14440-47-2
• 化学式: C₉H₇ClO₄
• mdl: MFCD01743493
• 分子量: 214.605
• InChiKey: VXVIICNFYDEOJG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  (4-氯-2-甲酰基苯氧基)乙酸 在 sodium hydroxide 、 sodium tetrahydroborate 作用下， 生成 座果酸
  参考文献：
  名称：

  磷酸吡rid醛。二。苯类似物。2-甲酰基苯氧基乙酸作为吡ido醛磷酸的潜在抗代谢物。

  摘要：

  DOI：

  10.1021/jm00303a018
• 作为产物：
  描述：

  (4-chloro-2-formyl-phenoxy)-acetic acid ethyl ester 在 sodium hydroxide 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 生成 (4-氯-2-甲酰基苯氧基)乙酸
  参考文献：
  名称：

  Synthesis and aldose reductase inhibitory activity of a new series of 5-[[2-(ω-carboxyalkoxy)aryl]methylene]-4-oxo-2-thioxothiazolidine derivatives

  摘要：

  A new series of 5-[[2-(omega-carboxyalkoxy)aryl]methylene]-4-oxo-2-thioxothiazolidine derivatives was synthesized and evaluated for their potency as aldose reductase inhibitors (ARIs). Their activities were examined in terms of their inhibitory effect on rat lens aldose reductase in vitro and in terms of the preventive effect on sorbitol accumulation in the sciatic nerve of streptozotocin (STZ)-induced diabetic rats in vivo. Of these compounds, some of the naphthylmethylene thiazolidine derivatives were comparable to Zenarestat in the inhibitory potency in vitro and in vivo. In particular, compound 30 was 1.5 times more potent than Zenarestat in the in vivo activity, and had an adequate potency for clinical development. (C) 1999 Editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(99)00128-2

文献信息

• Design, Synthesis, and Biological Evaluation of Thiazolidine-2,4-dione Conjugates as PPAR-γ Agonists
  作者：Syed Nazreen、Mohammad Sarwar Alam、Hinna Hamid、Mohammad Shahar Yar、Abhijeet Dhulap、Perwez Alam、Mohammad Abdul Qadar Pasha、Sameena Bano、Mohammad Mahboob Alam、Saqlain Haider、Chetna Kharbanda、Yakub Ali、Kolakappi Pillai

  DOI：10.1002/ardp.201400280

  日期：2015.6

  A library of synthesized conjugates of phenoxy acetic acid and thiazolidinedione 5a–m showed potent peroxisome proliferator activated receptor‐γ (PPAR‐γ) transactivation as well as significant blood glucose lowering effect comparable to the standard drugs pioglitazone and rosiglitazone. Most of the compounds showed higher docking scores than the standard drug rosiglitazone in the molecular docking

  苯氧基乙酸和噻唑烷二酮 5a-m 的合成偶联物库显示出有效的过氧化物酶体增殖物激活受体-γ（PPAR-γ）反式激活以及与标准药物吡格列酮和罗格列酮相当的显着降血糖作用。在分子对接研究中，大多数化合物显示出比标准药物罗格列酮更高的对接分数。与标准药物吡格列酮和罗格列酮相比，化合物 5l 和 5m 的 PPAR-γ 反式激活率分别为 54.21% 和 55.41%，分别显示 65.94% 和 82.21% 的激活率。化合物 5l 和 5m 显着降低了 STZ 诱导的糖尿病大鼠的血糖水平。与标准药物吡格列酮相比，化合物 5l 和 5m 降低了 AST、ALT 和 ALP 水平。与标准药物吡格列酮（1.5 倍）和罗格列酮（1.0 倍）相比，化合物 5m（2.00 倍）显着增加了 PPAR-γ 基因表达。化合物 5l 和 5m 不会对肝脏造成任何损害，可被视为开发新型抗糖尿病药物的有希望的候选物。
• [EN] 2, 3, 4, 5-TETRAHYDROBENZO[F][1, 4]OXAZEPINE-5-CARBOXYLIC ACID AMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] DERIVES D'AMIDE D'ACIDE 2, 3, 4, 5-TETRAHDROBENZO`F! `1, 4!OXAZEPINE-5-CARBOXYLIQUE TENANT LIEU D'INHIBITEURS DE LA GAMMA-SECRETASE POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：HOFFMANN LA ROCHE

  公开号：WO2004100958A1

  公开（公告）日：2004-11-25

  The invention relates to benzoxazepinone derivatives of formula (I) wherein R1 is hydrogen, lower alkoxy, halogen or -NR'R'; n is 1 or 2; R',R' are independently from each other hydrogen or lower alkyl; R2 is hydrogen, lower alkyl, -(CH2)m-cycloalkyl, -(CH2)m-phenyl or -(CH2)m-O-lower alkyl; m is 0,1or 2; R3 is lower alkyl, -(CH2)m-C(O)O-lower alkyl, cycloalkyl or -(CH2)m-phenyl, which is unsusbtituted or substituted by one or two substituents, selected from the group consisting of halogen or lower alkyl; R4 is -(CH2)ο-phenyl, which is unsusbtituted or substituted by one or two substituents, selected from the group consisting of halogen, trifluoromethyl, -NR'R', nitro or _SO2NH2, or is - cycloalkyl, unsubstituted or substituted by phenyl, or is - (CR'R')ο-heterocyclyl, selected from the group defined in claim 1 and o is 1 or 2; and to pharmaceutically suitable acid addition salts thereof. These compounds are good Ϝ-secretase inhibitors for the treatment of Alzheimer's disease.

  本发明涉及公式（I）的苯并噁唑啉酮衍生物，其中R1为氢、低碳氧基、卤素或-NR'R'；n为1或2；R'，R'各自独立地为氢或低碳基；R2为氢、低碳基、-(CH2)m-环烷基、-(CH2)m-苯基或-(CH2)m-O-低碳基；m为0、1或2；R3为低碳基、-(CH2)m-C（O）O-低碳基、环烷基或-(CH2)m-苯基，未经置换或经过一或两个置换基从卤素或低碳基的群中选择；R4为-(CH2)ο-苯基，未经置换或经过一或两个置换基从卤素、三氟甲基、-NR'R'、硝基或_SO2NH2的群中选择，或为-环烷基，未经置换或经过苯基置换，或为-(CR'R')ο-杂环基，从权利要求1中定义的群中选择，o为1或2；以及其药学上适宜的酸盐。这些化合物是治疗阿尔茨海默病的良好Ϝ-分泌酶抑制剂。
• Benzoxazepinone derivatives
  申请人：——

  公开号：US20040235819A1

  公开（公告）日：2004-11-25

  The invention relates to benzoxazepinone derivatives of formula 1 wherein R 1 , R 2 , R 3 , R 4 , and n are as defined in the specification and to a pharmaceutically suitable acid addition salt thereof. These compounds are good &ggr;-secretase inhibitors for the treatment of Alzheimer's disease.

  该发明涉及公式1中的苯并噁唑酮衍生物，其中R1，R2，R3，R4和n如规范中所定义，并且其药物适宜的酸盐。这些化合物是治疗阿尔茨海默病的良好&ggr;-分泌酶抑制剂。
• Piperidine derivatives and their use as anti-inflammatory agents
  申请人：Arnaiz O. Damian

  公开号：US20060167044A1

  公开（公告）日：2006-07-27

  Piperidine derivatives of the following formulae I and II: and their pharmaceutically acceptable salts, which are functional antagonists of the CC chemokine receptor CCR1 and are thus useful as anti-inflammatory agents, a pharmaceutical compositions containing said piperidine derivatives or their pharmaceutically acceptable salts, and methods of their use.

  以下公式I和II的哌啶衍生物及其药学上可接受的盐，它们是CC趋化因子受体CCR1的功能性拮抗剂，因此可用作抗炎剂。药物组合物包含上述哌啶衍生物或其药学上可接受的盐，并且使用它们的方法。
• Phenoxyacetic Acid Derivatives Useful for Treating Respiratory Diseases
  申请人：Alcaraz Lilian

  公开号：US20090149448A1

  公开（公告）日：2009-06-11

  The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.

  本发明涉及用于治疗呼吸系统疾病的取代苯氧乙酸类化合物作为有用的药物化合物，包含这些化合物的药物组合物以及它们的制备方法。